Hubei Yuancheng Saichuang Technology Co.,Ltd.

Hubei Yuancheng Saichuang Technology Co.,Ltd.

You are here: HomeProductsMK-677

Contact us

  • Company Name: Hubei Yuancheng Saichuang Technology Co.,Ltd.
  • Street: Wuchang
  • City: Wuhan
  • Province/state: Hubei
  • Country/region: China
  • Contact Person: Ms.Merry Zhou
  • Department: Sales
  • Tel: 86-27-50756228
  • Fax: 86-27-88048077
  • Email:

MK-677

  • CAS No:159752-10-0 MK-677
    Molecular Structure

    Detailed Description

    Ibutamoren(MK-677)
    Synonyms: MK-677;2-Amino-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methylpropanamide methanesulfonate;(R)-1'-(2-Methylalanyl-O-benzyl-D-seryl)-1-(Methylsulfonyl)-1,2-dihydrospiro[indole-3,4'-piperidine] Mesylate;Crescendo;IbutaMoren Mesylate(MK-677)
    CAS: 159752-10-0
    MF: C27H36N4O5S.CH4O3S
    MW: 624.776
    Chemical Properties Pale Yellow Solid
    Usage It is a potent and tissue-selective androgen receptor modulator (SARM)


    Nutrobal (MK-677) is an orally administrated growth / hormone secretagogue originally developed by Reverse Pharmacology. A secretagogue is the term for a substance that chemically signals for the pituitary gland to secrete . In other words, MK-677 could be compared to peptides like GHRP-6 or Ipamorelin, only it doesn't require any injections nor does it have any side effects like GHRP-6. This GHS (Growth / Hormone Secretagogue) was developed in an aim to combat such conditions as muscle wasting, obesity and osteoporosis. It was also targeted towards treatment of elderly hip fracture patients, so there are a myriad of studies done on safety.


    Name CAS NO. Usage
    AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
    MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
    MK-677 15972-10-0 A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
    LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
    GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
    Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
    SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
    SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
    RAD140 1182367-47-0 New generation for gaining mass and cutting edges
    YK11 366508-78-3 YK11: a SARM and myostatin inhibitor in one
    431579-34-9
  • MK-677
  • MK-677